Home / News / Global Diagnostics and Therapeutics For Lung Cancer Market is expected to grow at the CAGR of 8% during 2015-2022 – Brisk Insights

Global Diagnostics and Therapeutics For Lung Cancer Market is expected to grow at the CAGR of 8% during 2015-2022 – Brisk Insights

According to a recently published report, the Global Diagnostics and Therapeutics For Lung Cancer Market is expected to grow at the CAGR of 8% during 2015-2022. The global diagnostics and therapeutics for lung cancer market is segmented on the basis of drug type and geography. The report on Global Diagnostics and Therapeutics for Lung Cancer market forecast, 2012-2022 (by drug type, geography) provides detailed overview and predictive analysis of the market.

The global diagnostics and therapeutics for lung cancer market is expected to grow at the CAGR of 8% during 2015-2022. The global market is driven by increasing adoption of personalized treatments. Although new drugs have revitalized the lung cancer therapeutics market, patent expiry of existing drugs has posed a major threat to original drug manufacturers. NSCLC, often the most dreaded of all types of lung cancer, is highly likely to metastasize into the bones and other tissues, making it difficult to detect and treat. NSCLC accounts for 90% of all lung cancer cases. Drugs used in the treatment of NSCLC range from regular regimens to targeted therapies.

Full report available global Diagnostics and Therapeutics for Lung Cancer market forecast, 2012-2022 (by drug, and geography) report at http://www.briskinsights.com/report/diagnostics-and-therapeutics-for-lung-cancer-market

The market for diagnostics and therapeutics for lung cancer market is segmented as follows: by drug type and by geography. Angiogenesis inhibitor was the largest segment of the global non-small cell lung cancer market presently. The key players in the global diagnostics and therapeutics for lung cancer market include Genentech, Inc. ( a Roche Company), Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly and Company, Pfizer, Inc., Novartis AG, Astra Zeneca plc, and Celgene Corporation.

Scope of the Report

1. Global diagnostics and therapeutics for lung cancer market by types of drugs, 2012 – 2022
1.1. Angiogenesis Inhibitor Market
1.2. EGFR Blockers Market
1.3. Kinase Inhibitor Market
1.4. Microtubule Stabilizer Market
1.5. Folate Antimetabolites Market
1.6. PD-1/PD-L1 Inhibitor Market

2. Global Diagnostics and Therapeutics for Lung Cancer market, regional outlook, 2012-2022 ($ BILLION)
2.1. North America
2.2. Europe
2.3. Asia Pacific
2.4. Middle East & Africa
2.5. Central & South America

3. Competitive Landscape
3.1. Astra Zeneca PLC
3.2. Boehringer Ingelheim
3.3. Bristol-Myers Squibb
3.4. Celgene Corporation
3.5. GlaxoSmithKline PLC
3.6. Eli Lilly & Co.
3.7. Pfizer, Inc.
3.8. Genentech, Inc. (a Roche company)
3.9. Sun Pharmaceutical Industries Ltd.3D Systems

Global Diagnostics and Therapeutics For Lung Cancer Market is expected to grow at the CAGR of 8% during 2015-2022 – Brisk Insights reviewed on March 14, 2016 by rated 5.0 of 5

Release ID: 1003

About Anuradha Shukla

Check Also

400-400

Global X-Ray Equipment Market Is Expected To Reach USD 11,752.2 Mn By 2022 – Credence Research

The latest market report published by Credence Research, Inc. “Global X-ray Equipment Market – Growth, ...

Leave a Reply